Creonate Manufacturing

Born in 2022 through the opportunity to secure the future of a completely unique manufacturing initiative created by Global Access Diagnostics during the pandemic of 2020 and 2021. Established as a social enterprise, dedicated to securing and prioritising the provision of diagnostic products and components for developing countries to ensure that local manufacturing initiatives can operate unimpeded by mature market greed, while offering surge capacity backup, these core principles remain steadfastly the foundations of Creonate. High Volume? No Problem. Building further on the manufacturing scale up that occurred in 2021 with support from the UK Government, our 2-million-per-day volume facility is now the largest independent open-source diagnostics manufacturing capability in Europe. Specialising in the production of rapid diagnostics components and with access to bioreagents (and agnostic of type, be that Antibodies, Fragments, Affimers or MIPs), the facility is further differentiated by its ability to address manufacturing requirement from small scale, batch production of 100’s of devices, through to 100,000’s and more per batch through reel-to-reel production and automated assembly. It’s not just simple ‘two line’ diagnostics that have been mastered, but multiple analyte test production has also been a focus since inception. Cutting edge diagnostics for respiratory disease and infection (sepsis) have been produced for use within clinical trials, which present measurement results of up to 5 antigens per test strip, plus of control line.